In this randomized , positive - and placebo-controlled crossover study , healthy men received a single dose of naloxegol 25 mg ( therapeutic dose ) , naloxegol 150 mg ( supratherapeutic dose ) , moxifloxacin 400 mg ( positive control ) , or placebo in 1 of 4 sequences ( Williams Latin square design ) .